Viracta Therapeutics Inc (VIRX)

$0.17 -0.01 (-6.06%)
Market Cap 6.71M
Revenue (ttm) 0.00
Net Income (ttm) -51.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.55
Volume 1,404,500
Avg Vol 2,912,944
Day's Range N/A - N/A
Shares Out 39.74M
Stochastic %K 19%
Beta 0.66
Analysts Sell
Price Target $2.50

Latest News on VIRX

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Dec 26, 2024, 4:30 PM EST - 23 days ago

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 7:00 AM EST - 2 months ago

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 7:05 AM EDT - 5 months ago

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Aug 14, 2024, 7:00 AM EDT - 5 months ago

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Announces New Employment Inducement Grants

May 17, 2024, 4:05 PM EDT - 8 months ago

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

May 14, 2024, 7:00 AM EDT - 8 months ago

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:05 PM EDT - 9 months ago

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

May 7, 2024, 4:05 PM EDT - 9 months ago

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

Apr 15, 2024, 8:00 AM EDT - 9 months ago

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

Apr 1, 2024, 8:30 AM EDT - 10 months ago

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 7, 2024, 4:05 PM EST - 11 months ago

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

Feb 29, 2024, 8:00 AM EST - 11 months ago

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:05 PM EST - 1 year ago

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Jan 4, 2024, 8:00 AM EST - 1 year ago

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

Dec 12, 2023, 8:00 AM EST - 1 year ago

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

Dec 4, 2023, 8:30 AM EST - 1 year ago

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 8:30 AM EST - 1 year ago

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Viracta Therapeutics to Present at Upcoming Investor Conferences

Nov 7, 2023, 4:15 PM EST - 1 year ago

Viracta Therapeutics to Present at Upcoming Investor Conferences

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

Oct 4, 2023, 7:00 AM EDT - 1 year ago

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

Viracta Therapeutics to Host R&D Day on October 4, 2023

Sep 5, 2023, 9:00 AM EDT - 1 year ago

Viracta Therapeutics to Host R&D Day on October 4, 2023

Viracta Therapeutics Announces New Employment Inducement Grant

Aug 18, 2023, 4:05 PM EDT - 1 year ago

Viracta Therapeutics Announces New Employment Inducement Grant

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 8:00 AM EDT - 1 year ago

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Aug 8, 2023, 8:30 AM EDT - 1 year ago

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

Viracta Therapeutics Appoints Darrel P. Cohen, M.D.

Aug 7, 2023, 7:30 AM EDT - 1 year ago

Viracta Therapeutics Appoints Darrel P. Cohen, M.D.

Viracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

Jun 28, 2023, 8:00 AM EDT - 1 year ago

Viracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 4:15 PM EDT - 1 year ago

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

May 8, 2023, 4:05 PM EDT - 1 year ago

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Viracta Therapeutics Announces Departure of Chief Medical Officer

May 2, 2023, 4:05 PM EDT - 1 year ago

Viracta Therapeutics Announces Departure of Chief Medical Officer

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 19, 2023, 4:30 PM EDT - 1 year ago

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Mar 13, 2023, 4:05 PM EDT - 2 years ago

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

Mar 8, 2023, 4:05 PM EST - 2 years ago

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Feb 7, 2023, 4:05 PM EST - 2 years ago

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

Jan 19, 2023, 8:30 AM EST - 2 years ago

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Jan 8, 2023, 1:00 PM EST - 2 years ago

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

Nov 30, 2022, 6:10 PM EST - 2 years ago

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

Nov 10, 2022, 4:05 PM EST - 2 years ago

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

Sep 19, 2022, 8:00 AM EDT - 2 years ago

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma

Sep 7, 2022, 9:00 AM EDT - 2 years ago

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

Aug 16, 2022, 4:15 PM EDT - 2 years ago

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Aug 11, 2022, 9:00 AM EDT - 2 years ago

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Aug 9, 2022, 8:30 AM EDT - 2 years ago

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award

Jun 13, 2022, 4:15 PM EDT - 2 years ago

Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award

Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting

Jun 2, 2022, 8:30 AM EDT - 2 years ago

Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting

Viracta Therapeutics to Present at Upcoming May Investor Conferences

May 11, 2022, 4:05 PM EDT - 2 years ago

Viracta Therapeutics to Present at Upcoming May Investor Conferences

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

May 10, 2022, 4:05 PM EDT - 2 years ago

Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates

Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Apr 7, 2022, 10:13 AM EDT - 3 years ago

Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Mar 9, 2022, 4:30 PM EST - 3 years ago

Viracta Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Feb 10, 2022, 9:00 AM EST - 3 years ago

Viracta Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Jan 31, 2022, 8:30 AM EST - 3 years ago

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Jan 4, 2022, 9:00 AM EST - 3 years ago

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference